• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外周T细胞淋巴瘤的临床与病理诊断及新出现的治疗选择:基于病例的讨论

Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion.

作者信息

Said Jonathan, Pinter-Brown Lauren

机构信息

David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

出版信息

Clin Adv Hematol Oncol. 2009 Nov;7(11):S1, S4-13; quiz S15.

PMID:20095101
Abstract

The diverse group of peripheral T-cell lymphomas (PTCLs) present clinical and pathologic challenges. Proper recognition and diagnosis can be difficult even for experienced pathologists because these entities tend to vary in morphologic appearance from case to case within the same subtype and often mimic other diseases in appearance. This makes the use of immunologic markers an essential tool. Clinically, PTCLs are difficult to treat because they often present in an advanced stage and are resistant to traditional first-line chemotherapeutic regimens. Five-year overall survival rates are dismal, ranging from 20-50%, depending upon subtype. Although high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation has been reported to improve overall survival in patients with PTCL, this therapy is only feasible for the small minority of patients who experience a durable complete response to induction therapy. Therefore, there is much interest in the field in developing novel first-line approaches that will improve response rates and duration. In this monograph, 2 case studies of different subtypes of PTCL will be presented, and the clinical and pathologic features will be discussed. In addition, data on emerging therapies for PTCLs will be reviewed with an emphasis on novel and investigational agents.

摘要

外周T细胞淋巴瘤(PTCL)种类多样,在临床和病理方面都具有挑战性。即便对于经验丰富的病理学家而言,准确识别和诊断也可能存在困难,因为这些淋巴瘤在同一亚型内,不同病例的形态学表现往往各异,且外观上常与其他疾病相似。这使得免疫标记物的应用成为一项重要工具。在临床上,PTCL难以治疗,因为它们通常在晚期出现,并且对传统的一线化疗方案具有抗性。五年总生存率很低,根据亚型不同,在20%至50%之间。尽管有报道称,高剂量序贯化疗后进行自体造血干细胞移植可提高PTCL患者的总生存率,但这种治疗仅适用于少数对诱导治疗产生持久完全缓解的患者。因此,该领域对开发能提高缓解率和缓解持续时间的新型一线治疗方法有着浓厚兴趣。在本专著中,将展示2例不同亚型PTCL的病例研究,并讨论其临床和病理特征。此外,还将回顾PTCL新兴治疗方法的数据,重点关注新型和研究性药物。

相似文献

1
Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion.外周T细胞淋巴瘤的临床与病理诊断及新出现的治疗选择:基于病例的讨论
Clin Adv Hematol Oncol. 2009 Nov;7(11):S1, S4-13; quiz S15.
2
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.复发侵袭性淋巴瘤的治疗:含与不含高剂量治疗及干细胞救援的方案
Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12.
3
Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.血管免疫母细胞性T细胞淋巴瘤患者经大剂量化疗和自体干细胞移植后的长期生存:GELTAMO研究经验
Eur J Haematol. 2007 Apr;78(4):290-6. doi: 10.1111/j.1600-0609.2007.00815.x.
4
Enhancing existing approaches to peripheral T-cell lymphoma.增强外周 T 细胞淋巴瘤的现有治疗方法。
Semin Hematol. 2010 Apr;47 Suppl 1:S8-10. doi: 10.1053/j.seminhematol.2010.01.012.
5
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.外周T细胞淋巴瘤患者的大剂量自体干细胞移植治疗
Bone Marrow Transplant. 2001 Apr;27(7):711-6. doi: 10.1038/sj.bmt.1702867.
6
High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.诱导化疗后未达完全缓解的外周T细胞淋巴瘤患者的大剂量化疗及自体干细胞移植。GEL-TAMO研究经验。
Haematologica. 2003 Dec;88(12):1372-7.
7
Current treatment of peripheral T-cell lymphoma.外周T细胞淋巴瘤的当前治疗方法。
Clin Adv Hematol Oncol. 2011 Aug;9(8 Suppl 16):1-15.
8
High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.高剂量化疗及自体干细胞移植治疗外周T细胞淋巴瘤:移植时达到完全缓解可预测生存情况。
Ann Hematol. 2007 Jun;86(6):435-42. doi: 10.1007/s00277-007-0254-1. Epub 2007 Jan 26.
9
Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.采用大剂量化疗及自体或异基因造血移植治疗外周T细胞淋巴瘤(PTCL)。
Ann Hematol. 2002 Nov;81(11):646-50. doi: 10.1007/s00277-002-0556-2. Epub 2002 Nov 9.
10
Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.外周T细胞淋巴瘤:基于病例探讨患者管理的最新进展
Clin Adv Hematol Oncol. 2011 Apr;9(4 Suppl 9):1-16.

引用本文的文献

1
Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.基因组分析显示,表达 ITK-SYK 融合基因的外周 T 细胞淋巴瘤中 IL2RG/JAK3/STAT5 的激活。
Int J Oncol. 2019 Nov;55(5):1077-1089. doi: 10.3892/ijo.2019.4882. Epub 2019 Sep 20.
2
Primary gastrointestinal lymphoma.原发性胃肠道淋巴瘤。
World J Gastroenterol. 2011 Feb 14;17(6):697-707. doi: 10.3748/wjg.v17.i6.697.